Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2023-09-28

Clinical Trial Update: The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating an antioxidant combination (ASTED) for Thyroid Eye Disease was withdrawn during Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASTED

Snippet

Sponsor: Iran University of Medical Sciences | Conditions: Thyroid Eye Disease | Phase 2, Phase 3 | Status: WITHDRAWN